4[1]Kwiatkowki TG, Libman RB, Frankel M et al. Effects of Tissue plasminogen activator for acute ischemic stroke at one year. N Eng1 J Med, 1999; 340:1781～1787
5[2]Clark WM, Wissman S, Albers GW et al. Recombinant Tissue-Type plasminogen activator(Alteplase)for ischemic stroke 3 to 5 hours after symptom onset. The Atlantis study: A randomized controlled trial. JAMA, 1999; 282:2019～2026
6[3]Clark WM, Albers GW, Modden KP et al. The rtPA(Alteplase)0-to 6-hour acute stroke trial part A(A0276g). Results of a double-blind, placebo-controlled, multicenter study. Stroke, 2000; 31:811～816
7[4]Schlaug G, Siewert B, Benfield A et al. Time course of the apparent diffusion coefficient (ADC) abnormality in human stroke. Neurology, 1997; 49:113～119
8[5]Hoehn-Berlage M, Norris DG, Kohno K et al. Evolution of regional changes in apparent diffusion coefficient during focal ischemia of rat brain: The relationship of quantitative diffusion NMR imaging to reduction in cerebral blood flow and metabolic disturbances. J Cereb Blood Flow Metab, 1995; 15:1002～1011
9[6]van Lookeren Campagne M, Verheul HB, Vermeulen JP et al. Developmental changes in NMDA-indced cell swelling and its transition to necrosis with 1H magnetic resonance, impedance and histology. Brain Res Dev Brain Res, 1996;93:109～119
10[7]Li F, Liu KF, Silva MD et al. Transient and permanent resolution of ischemic lesions on diffusion-weighted imaging after brief periods of focal ischemia in rats. Correlation with histopathology. Stroke, 2000; 31:946～954
